Literature DB >> 34868884

Case report of a fulminant non-aneurysmal convexity subarachnoid hemorrhage after COVID-19.

Maximilian Scheer1, Anja Harder2, Sabine Wagner3, Richard Ibe4, Julian Prell1, Christian Scheller1, Christian Strauss1, Sebastian Simmermacher1.   

Abstract

We report on a case of a fulminant non-aneurysmal subarachnoid hemorrhage after COVID-19 in a patient without previous medical history or known previous illness despite a COVID-19 infection one month prior. We saw rarefied vessels in the area of the left middle cerebral artery besides a massive left frontal hemorrhage on cranial imaging. We concluded that these rarefied vessels are the expression of an RCVS, which fits the history of progressive headaches for one month. The RCVS might be caused by the COVID-19 infection and is related to the hemorrhage. Unfortunately, due to preoperative entrapment, brain death occurred a few days later.
© 2021 The Authors. Published by Elsevier B.V.

Entities:  

Keywords:  COVID-19; Case report; Subarachnoid hemorrhage

Year:  2021        PMID: 34868884      PMCID: PMC8628370          DOI: 10.1016/j.inat.2021.101437

Source DB:  PubMed          Journal:  Interdiscip Neurosurg        ISSN: 2214-7519


Introduction

Respiratory symptoms in combination with fever, cough, and fatigue are the most common symptoms of COVID-19 infections [1]. Central nervous system (CNS) involvement in patients suffering from coronavirus disease 2019 (COVID-19) has been reported in several studies and can lead to neurological symptoms such as headache, dizziness, hypogeusia, or hyposmia [2], [3]. Severe neurological conditions like stroke and vascular events have also been observed [2], [4]. Intracranial hemorrhage occurs in about 4.4% of COVID-19 patients and typically affects elderly persons with comorbidities and anticoagulation [5]. Nearly 80% of those hemorrhages are associated with ischemic stroke [6]. Brain herniation is the consequence in very few cases (0.7%). Some authors propose a higher incidence of aneurysmal and non-aneurysmal subarachnoid hemorrhage (SAH) in patients with COVID-19. It is debated whether an increase in incidence is a coincident finding or a confident correlation [7], [8]. We report on a case with a fulminant non-aneurysmal subarachnoid hemorrhage in a patient without previous medical history or known previous illness despite a COVID-19 infection one month prior.

Case report

A 56-year-old patient with no previous medical history presented with a Glasgow Coma Scale (GCS) of 3. The last contact with relatives was the evening before. One month ago, he suffered from mild respiratory symptoms, and COVID-19 was diagnosed. The relatives reported that the patient had reported progressive headaches after the COVID-19 illness with episodes of most severe holocephalic headaches (thunderclap headache). A treatment or evaluation prior to this admission for headache did not happen. At admission, COVID-PCR was weakly positive (ct value: 37), and d-dimer was elevated (2.14 µg/ml (reference < 0.5)). Coagulation parameters (PTT, INR, CT) and thrombocyte were within normal limits. The CT scan documented a massive, left frontal hemorrhage causing a dramatic midline shift which we thought was most likely an intracerebral hemorrhage (Fig. 1 ). No vascular malformation and no perfusion alterations were detected by CT angiography (CTA). But rarefied vessels on the left side in the area of the anterior and middle cerebral artery were seen (Fig. 2 ). Immediate surgery revealed not the suspected intracerebral hemorrhage but a massive space-occupying subarachnoid hemorrhage. The cortex appeared pale. No intracerebral hemorrhage was found (Fig. 3 ). Histologically, an old hematoma with additional fresh portions was confirmed, while there was no evidence of vascular disease, vascular malformation, or neoplasia. Postoperative CT demonstrated complete removal of the hemorrhage but massive strokes in the anterior, middle and posterior cerebral artery supply zone as a result of the preoperative entrapment (Fig. 4 ). Brain death was diagnosed three days after surgery.
Fig. 1

Preoperative CT scan of the brain on admission. Axial (A,B), coronal (C) and sagitall (D) cross-section image showing a massive left frontal hemorrhage with consecutive midline displacement. Imaging suggested intracerebral hemorrhage.

Fig. 2

CT angiography (CTA) scan of the brain on admission. (A) Axial cross-section image with multiplanar reconstruction (MPR) of the CTA showing abnormal narrowing of the left middle cerebral artery (open arrow) compared to the normal width of the right middle cerebral artery (solid arrow). (B) Sagittal MPR, revealing segmental narrowing and dilatation of the anterior cerebral arteries with a string-of-beads appearance (arrowheads).

Fig. 3

Image of intraoperative findings showing massive subarachnoid hemorrhage rather than the intracerabral hemorrhage suspected on imaging. The cortex can be identified in depth (arrowhead).

Fig. 4

Postoperative CT scan of the brain. Axial cross-section image showing complete removal of subarachnoid hemorrhage but anterior, middle, and posterior cerebral artery stroke.

Preoperative CT scan of the brain on admission. Axial (A,B), coronal (C) and sagitall (D) cross-section image showing a massive left frontal hemorrhage with consecutive midline displacement. Imaging suggested intracerebral hemorrhage. CT angiography (CTA) scan of the brain on admission. (A) Axial cross-section image with multiplanar reconstruction (MPR) of the CTA showing abnormal narrowing of the left middle cerebral artery (open arrow) compared to the normal width of the right middle cerebral artery (solid arrow). (B) Sagittal MPR, revealing segmental narrowing and dilatation of the anterior cerebral arteries with a string-of-beads appearance (arrowheads). Image of intraoperative findings showing massive subarachnoid hemorrhage rather than the intracerabral hemorrhage suspected on imaging. The cortex can be identified in depth (arrowhead). Postoperative CT scan of the brain. Axial cross-section image showing complete removal of subarachnoid hemorrhage but anterior, middle, and posterior cerebral artery stroke.

Discussion

COVID-19 usually affects the CNS mildly with the leading symptoms of headache and/or hyposmia [3]. Additionally, vascular events like thrombosis of the cerebral venous sinus and reversal cerebral vasoconstriction syndrome (RCVS) are described in COVID-19 patients. It is suggested that thrombosis is mediated by a cytokine storm or by endothelial damage. Resulting cascade activation is leading to hypercoagulation [9], [10], [11]. Hypercoagulation might lead to ischemic stroke and increased risk of a secondary intracerebral hemorrhage [5], [12], [13]. However, intracranial hemorrhage is rare in patients with COVID-19 and is typically associated with risk factors such as arterial hypertension and anticoagulation therapy [4], [5], [6], [7]. In our case, ischemic stroke was not observed on the primary ct scan. The initially elevated d-dimer levels in our patent may indicate a thrombosis of cerebral venous, but this could not be confirmed by CT angiography. A sinus vein thrombosis could cause a subarachnoid or intracerebral hemorrhage [14], [15]. Furthermore, a higher incidence of aneurysmal SAH in COVID-19 patients is suspected by some authors [7], [16]. Acute onset of thunderclap headache is typical for SAH. Four weeks after recovery from a COVID-19 infection, this patient suffered from progressive headaches for about one month with episodes of most severe holocephalic headaches (thunderclap headache). Recurrent thunderclap headache is typical for RCVS caused by constriction of cerebral arteries [17]. Global or segmental vasoconstriction is not directly caused by COVID-19 but COVID-19 is attributed for down-regulation of angiotensin-converting enzyme (ACE)-2 receptors, leading to sympathetic hypertonia of the cerebral vessels and/or over activation of the classic renin-angiotensin axis resulting in vasoconstriction [18]. RCVS can lead to complications like posterior reversible encephalopathy syndrome (PRES), seizures, ischemic stroke, intracerebral hemorrhage, and convexity subarachnoid hemorrhage (cSAH) [19]. cSAH is described as a typical subtype of non-aneurysmal SAH and is commonly caused by RCVS in 60-year-old patients or younger [20]. Administration of Nimodipine and Aspirin may be used for the treatment of RCVS [19]. Our patient died because of a massive cerebral infarction caused by intracranial hypertension following massive cSAH. To sum up, we saw rarefied vessels in the area of the left middle cerebral artery besides a massive left frontal hemorrhage on cranial imaging. We concluded that these rarefied vessels are the expression of an RCVS, which fits the history of progressive headaches for one month. The RCVS might be caused by the COVID-19 infection and is related to the hemorrhage. To avoid the development of RCVS and hypercoagulability in patients with or after recovery from COVID-19 a regular headache history should be taken and if symptoms occur oral anticoagulation, antiplatelet therapy, or prophylaxis of vasospasm with Nimodipine should be considered, depending on the individual risk profile and cranial imaging [19], [21], [22], [23].

Conclusion

COVID-19 is suggested to raise the risk of hemorrhage after stroke and the incidence of aneurysmal SAH. The described case shows, that RCVS and cSAH are possible complications after COVID-19 infection with potentially fatal outcomes. We conclude that even in the case of mild course of COVID-19, especially young patients should be advised that recurrent headache and particularly thunderclap headache is a typical symptom of RCVS which can lead to seizure, stroke or convexity subarachnoid hemorrhage. Early detection of RCVS rises the possibility for successful treatment.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  23 in total

1.  Predictors of outcome in patients with cerebral venous thrombosis and intracerebral hemorrhage.

Authors:  Marie Girot; José M Ferro; Patrícia Canhão; Jan Stam; Marie-Germaine Bousser; Fernando Barinagarrementeria; Didier Leys
Journal:  Stroke       Date:  2007-01-04       Impact factor: 7.914

2.  Atraumatic convexal subarachnoid hemorrhage: clinical presentation, imaging patterns, and etiologies.

Authors:  S Kumar; R P Goddeau; M H Selim; A Thomas; G Schlaug; A Alhazzani; D E Searls; L R Caplan
Journal:  Neurology       Date:  2010-03-16       Impact factor: 9.910

3.  Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology.

Authors:  Cristina Vieira; Lucas Nery; Ludimila Martins; Luiz Jabour; Raphael Dias; Ana Cristina Simões E Silva
Journal:  Curr Drug Targets       Date:  2021       Impact factor: 3.465

Review 4.  The Role of Anticoagulation in COVID-19-Induced Hypercoagulability.

Authors:  Juan Simon Rico-Mesa; Daniel Rosas; Ashkan Ahmadian-Tehrani; Averi White; Allen S Anderson; Robert Chilton
Journal:  Curr Cardiol Rep       Date:  2020-06-17       Impact factor: 2.931

Review 5.  Stroke as a complication and prognostic factor of COVID-19.

Authors:  J M Trejo-Gabriel-Galán
Journal:  Neurologia (Engl Ed)       Date:  2020-05-06

Review 6.  COVID-19 and stroke: A review.

Authors:  Xiaoming Qi; Kristin A Keith; Jason H Huang
Journal:  Brain Hemorrhages       Date:  2020-11-17

7.  Stroke in patients with COVID-19: Clinical and neuroimaging characteristics.

Authors:  Alberto Vogrig; Gian Luigi Gigli; Claudio Bnà; Mauro Morassi
Journal:  Neurosci Lett       Date:  2020-12-19       Impact factor: 3.046

Review 8.  COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.

Authors:  Wolfgang Miesbach; Michael Makris
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

9.  Concurrent Acute Ischemic Stroke and Non-Aneurysmal Subarachnoid Hemorrhage in COVID-19.

Authors:  Lennie Lynn C de Castillo; Jose Danilo B Diestro; Katrina Hannah D Ignacio; Karl Josef Niño J Separa; Paul Matthew D Pasco; Maria Carissa P Franks
Journal:  Can J Neurol Sci       Date:  2020-11-05       Impact factor: 2.104

View more
  2 in total

1.  Subarachnoid hemorrhage: management considerations for COVID-19.

Authors:  Eric J Panther; Brandon Lucke-Wold
Journal:  Explor Neuroprotective Ther       Date:  2022-03-02

Review 2.  Pathophysiology of reversible cerebral vasoconstriction syndrome.

Authors:  Shih-Pin Chen; Shuu-Jiun Wang
Journal:  J Biomed Sci       Date:  2022-09-21       Impact factor: 12.771

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.